secwatch.observer — SEC 8-K summary
======================================

Issuer:     Damora Therapeutics, Inc. (DMRA)
CIK:        0001800315
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001564590-22-000413
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
LLM model:  deepseek-v4-flash:cloud@v2

Galecto files updated corporate presentation for January 2022 investor meetings
-------------------------------------------------------------------------------

- Presentation titled 'First-in-class small-molecule anti-fibrotic and anti-cancer agents'.
- Filed under Regulation FD; presentation dated January 2022.
- No specific new financial or pipeline details disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800315/000156459022000413/0001564590-22-000413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800315/000156459022000413/glto-8k_20220105.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-000413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer